

## ***iLite*<sup>®</sup> VEGF Assay Ready Cells**

(REF: BM4021)

***For research use only. Not for use in diagnostic procedures.***

### **DESCRIPTION**

*iLite*<sup>®</sup> VEGF Assay Ready Cells is a human embryonic kidney cell line (HEK-293\*; ATCC #CRL-1573) that have been genetically engineered and optimized to respond to VEGF with specific, proportional expression of Firefly Luciferase

### **CONTENT**

>250µl of Assay Ready Cells suspended in cryoprotective medium from Amsbio (Cat. No 11888).

### **RECEIPT AND STORAGE**

Upon receipt confirm that adequate dry-ice is present, and the cells are frozen. Immediately transfer to -80°C storage. Cells should be stored at -80°C (**do not store at any other temperature**) and are stable as supplied until the expiry date shown. Cells should be used within 30 min of thawing.

### **BACKGROUND**

Vascular Endothelial Growth Factor (VEGF) is a signalling protein which is involved in both normal vascular growth and pathological angiogenesis. Without angiogenesis, growth of solid tumours would be limited by oxygen supply. Tumours which express VEGF can overcome this limitation and are thus able to grow and metastasize. For this reason, different anti-cancer therapies targeting VEGF have emerged, e.g. a humanized anti-VEGF antibody such as bevacizumab (Avastin<sup>™</sup>, Genentech) is currently widely used as a first-line therapy for colorectal cancer (1,2).

### **APPLICATION**

The *iLite*<sup>®</sup> VEGF Assay Ready Cells can be used for the quantification of VEGF activity, VEGF inhibitor activity and for determination of neutralizing antibodies against VEGF inhibitors in human serum.

Application notes for the following assays are available:

- Quantification of VEGF inhibitor activity using *iLite*<sup>®</sup> VEGF Assay Ready Cells (LABEL-DOC-0405)
- Determination of neutralizing antibodies against VEGF inhibitors using *iLite*<sup>®</sup> VEGF Assay Ready Cells (LABEL-DOC-0406)

## REFERENCES

1. Wang Y, Fei D, Vanderlaan M, Song A. *Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitro.* *Angiogenesis* 7:335-345 (2004).
2. Risau, W. *Mechanisms of angiogenesis.* *Nature* 386: 671 – 674 (1997).

## SYMBOLS ON LABEL

	Lot number		Temperature limitation
	Catalogue number		Biological risk
	Use by		Manufacturer

## PRECAUTIONS

For research use only. This product is intended for professional laboratory research use only. The data and results originating from using the product, should not be used either in diagnostic procedures or in human therapeutic applications.

*iLite*<sup>®</sup> VEGF Assay Ready Cells are a stable transfected cell line of human origin as a Class 1 Genetically Modified Microorganism. This is based on the conclusion that neither insert nor vector adds anything to the biosafety level since the cells cannot produce active virus. They should be handled in accordance with EU regulations (2009/41/EC) and disposed of in a licensed contained-use facility in accordance with these regulations. When used in accordance with the manufacturer's product specification, the requirements of EC Directive 2009/41/EC on the contained-use of genetically modified microorganisms are deemed to have been met.

Residues of chemicals and preparations generally considered as biohazardous waste and should be inactivated prior to disposal by autoclaving or using bleach. All such materials should be disposed of in accordance with established safety procedures.

## PROPRIETARY INFORMATION

In accepting delivery of *iLite*<sup>®</sup> Assay Ready Cells the recipient agrees not to sub-culture these cells, attempt to sub-culture them or to give them to a third party, and only to use them directly in assays. *iLite*<sup>®</sup> cell-based products are covered by patents which is the property of Svar Life Science AB and any attempt to reproduce the delivered *iLite*<sup>®</sup> Assay Ready Cells is an infringement of these patents.